

Products

Hartalega offers a range of products, superior in quality, and critical protection. There is no compromise in our manufacturing standards, in fact we are proud to consistently exceed international quality standards. This is why we are known and trusted, worldwide.

Gloves by Market Segment

Whether you are in manufacturing, healthcare or laboratory environment; you can enjoy comfort, protection, hygiene and cost-effectiveness in Hartalega's range of gloves.













Nitrile Gloves

Since 2002, Hartalega has been in the forefront of Nitrile gloves production. That's over a decade of producing the world's best Nitrile gloves, along with the introduction of major technological improvements in Nitrile glove manufacturing that has cemented our reputation the world over.

Read More

Latex Gloves

Before Hartalega focused primarily on producing nitrile gloves, we were already known for our exceptional quality latex gloves. In fact, our latex gloves were considered to be the 'gold standard' in terms of quality and consistency, and still are to this very day.

Read More



gloveen

The premium name in hand protection. GloveOn gloves are engineered with the greatest precision, reliability and attention to detail only because protection is never compromised.

DIMUN

Focused on high quality care giving for all, Mun is the global platform for premium health care brands. We come empowered with knowledge, expertise and experience gained from developing some of the best and most cutting edge products in the health care industry. Our goal is to share and provide the best quality health care products for the betterment of humanity.

Hartalega

Mun is birthed from a culture of excellence and innovation – the foundation to Hartalega's global success. This is proven by Hartalega's many unprecedented technological achievements in both process and product development. The same values of quality, passion, integrity, innovation, reliability and dedication found in Hartalega are embedded in the DNA of Mun.





Paloma

Nitrile, Powder Free, Standard Cuff, Non-Sterile, Fingertip Textured

≥ 230

Product Code - NTR 51 (Size)

Product Description - Nitrile, Powder Free, Standard Cuff, Non-Sterile, Fingertip Textured

Colour - White

Material - Synthetic Nitrile Rubber

Product Conformance - ASTM D6319

Packing Method - pcs per box by weight

10 boxes per carton (180 pcs per box for XL)

Specifications

Glove Length (mm)

Length (mm)

Glove Size (Palm Width) mm	
Extra Small	76 ± 4
Small	86 ± 4
Medium	98 ± 4
Large	107±4
Extra Large	115 ± 4

Thickness Measurements mm

Particulate Residue

Palm (Centre of Palm)	0.07 ± 0.02
Finger (13mm±3mm from tip)	0.09 ± 0.02

Physical Properties	Before Ageing	After Ageing
Tensile Strength (Mpa)	≥ 18	≥ 16
Elongation (%)	500	400
Inspection Levels & AQL	Inspection Level	AQL
Watertightness	G1	1.50
Physical Dimensions	S2	4.00
Tensile Strength	S2	4.00
Visual Inspection (Major)	54	2.50
Visual Inspection (Minor)	SA	4.00

N = 5

≤2mg/glove



Nitrile Examination Glove Powder Free



	GloveOn Paloma		
Length (mm)			
	≥ 230		
Thickness Measurements (mm)			
Palm (centre of Palm)	0.07 ±	0.02	
Finger (13mm ± 3mm from tip)	0.09 ±	0.02	
Physical Properties	Before Ageing	After Ageing	
Tensile Strength (MPa)	≥ 18	≥ 16	
Elongation (%)	≥ 500	≥ 400	
Inspection Levels & AQL	Inspection Level	AQL	
Watertightness	G1	1.5	
Physical Dimensions	S2	4.0	
Physical Properties	S2	4.0	
Visual Inspection (Major)	\$4	2.5	
Visual Inspection (Minor)	S4	4.0	
Particulate Residue	N = 5	< 2mg/glove	

Actual Dimension in millimetres (mm)

Made in Malaysia by Hartalega Sdn Bhd

Chemotherapy Drugs and Concentration (Tested for Resistance to Permeation by Chemotherapy Drugs as per ASTM 06978-05)	Minimum Breakthrough Detection Time (minutes
Carmustine (BCNU), 3.3mg/ml (3.300 ppm)	16.2 minutes
Cisplatin, 1.0mg/ml (1.000 ppm)	>240 minutes
Cyclophosphamide (Cytoxan), 20.0mg/ml (20,000 ppm)	>240 minutes
Dacarbazine (DTiC), 10.0mg/ml (10.000 ppm)	>240 minutes
Doxorubicin Hydrochloride, 2.0mg/ml (2,000 ppm)	>240 minutes
Etoposide (Toposar), 20.00mg/ml (20,000 ppm)	>240 minutes
Fluorouracit, 50.0mg/ml (50,000 ppm)	>240 minutes
Methotrexate, 25.0mg/ml (25,000 ppm)	>240 minutes
Mitomycin C, 0.5mg/ml (500 ppm)	>240 minutes
Paclitaxel (Taxol), 6.0mg/ml (6.000 ppm)	>240 minutes
Thiotepa. 10.0mg/ml (10.000 ppm)	28.4 minutes
Vincristine Sulfate, 1.0mg/ml (1,000 ppm)	>240 minutes

FEATURES

- Fingertip textured
- · Powder free
- · Not made with natural rubber latex
- · Chemo drugs tested
- · Lab chemical tested
- Ambidextrous
- Violet blue colour
- Food Safe

PACKAGING

100 gloves per box 10 boxes per carton

REGULATORY COMPLIANCE

FDA 510(k), MDD 93/42/EEC, REACH, ROHS Directive 2002/95/EC, EC 10/2011, EC 1935/2004

STANDARDS

ASTM D6319, ASTM D412, ASTM D573, ASTM D5151, ASTM D6124, EN455 part 1, 2, 3 & 4, EN 1186, EN 13130, CEN/TS 14234

MANUFACTURING ACCREDITATIONS

ISO 9001 ISO 13485 EN ISO 13485

WARNING. Carmustine and Thiotepa, at the tested concentration, degraded Paloma nitrile glove at 16.2 minutes and 28.4 minutes respectively. The safe use of gloves in chemotherapy treatment is solely the decision of clinicians authorised to make such a decision







EC Declaration of Conformity

We, the manufacturer

Hartalega Sdn. Bhd., No. 7, Kawasan Perusahaan Suria, 45600 Bestari Jaya, Selangor Darul Ehsan, Malaysia

with European Representative

Medical Device Safety Service (MDSS) Schiffgraben 41, 30175 Hannover, Germany

Declares that the new PPE described hereafter

Category III (Type C)
HSB-TF-005
≥ 2.0 mil Powder Free Nitrile disposable five fingered glove
Available in a longer cuff variant

is in conformity with the relevant Union harmonisation legislation

PPE Regulation (EU) 2016/425

where such is the case, with the national standard transposing harmonized standard number

EN 420: 2003+A1: 2009 EN ISO 374 – 1:2016 EN ISO 374 – 5:2016

The notified body SATRA Technology Centre with Notified Body Number of 2777 performed the EU type-examination (Module B) and issued the EU type-examination certificate 2777/13926-02/E00-00.

The PPE is subject to the conformity assessment procedure conformity to type based on internal production control plus supervised product checks at random intervals (Module C2) under surveillance of the Notified body SATRA Technology Centre with Notified Body Number of 2777.

Done at Hartalega Sdn. Bhd. on 31st January 2020.

Kuan Eu Jin

Quality Management Representative





MDSS - Schiffgroben 41 - 30175 Hannover, Germany

Hartalega NGC Sdn Bhd. Khairunnisa Warsito No. 1, Persiaran Tanjung Kawasan Perindustrian Tanjung 43900 Sepang, Selangor MALAYSIA Schiffgroben 41 30175 Hannover, Germany

Tel: + 49 - 511 - 62 62 86 30 Fax: + 49 - 511 - 62 62 86 33

> eMail: info@mdss.com Internet: www.mdss.com

> > 2019.01.18

Confirmation of CE Registration

Dear Khairunnisa,

It is our pleasure to enclose the new Certificate of CE-Registration for your product.

Please note that registration was performed under § 25 MPG (Medizinproduktegesetz). This is the Federal Republic of Germany's national interpretation of Medical Device Directive 93/42/EEC. Registration is therefore in accordance with EU legislation. We remind you that all products must meet the applicable provision of the European and national regulation before they may be placed on the market.

We are looking forward to continuing our good business relationship and wish you a successful product launch in Europe.

Best regards,

Juan Monferrer Tena Administrative Assistant

Medical Device Safety Service GmbH

Encl.

1 Certificate of CE-Registration

1 Annex A

MDSS - Medical Device Safety Service GmbH Handelsregister Hannover HRB 57318 - USt-IdNr. DE 177346163 - Geschäftsführer: Ludger Möller

Bankverbindungen Sparkosse Honnover S.W.I.F.T.: SPKHDE2H IBAN: DE24 2505 0180 0910 0792 77

Commerzbank AG, Hannover S.W.I.F.T.: COBADEFF 250 IBAN: D667 2504 0066 0338 8816 00







Certificate of CE-Registration

This is to certify that, in accordance with the Medical Device Directive 93/42/EEC, Medical Device Safety Service GmbH (MDSS) agrees to perform all duties and responsibilities as the Authorized Representative for:

Hartalega NGC Sdn. Bhd. No. 1, Persiaran Tanjung Kawasan Perindustrian Tanjung 43900 Sepang, Selangor MALAYSIA

as stipulated and demanded by the aforementioned Directive. The German Competent Authority has allocated the medical devices of the Manufacturer registration numbers as foreseen in:

Annex A dated January 18, 2019

The Manufacturer has provided MDSS with the appropriate Declaration(s) of Conformity confirming that the medical devices fulfill the applicable requirements of Directive 93/42/EEC. In compliance with German law, a safety officer has been appointed for Germany.

2019-01-18

President MDSS GmbH

MDSS - Medical Device Safety Service - Schiffgraben 41 - 30175 Hannover, Germany



April 25, 2020

Hartalega NGC SDN. BHD. Nurul Kong Senior Manager- Quality Assurance Kawasan Perindustrian Tanjung Sepang, Selangor 43900 Malaysia

Re: K200581

Trade/Device Name: Paloma Nitrile Powder Free Examination Gloves (Blue)

Regulation Number: 21 CFR 880.6250

Regulation Name: Paloma Powder Free Examination Glove

Regulatory Class: Class I, reserved Product Code: LZA, LZC, QDO Dated: February 27, 2020

Received: March 5, 2020

Dear Nurul Kong:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

U.S. Food & Drug Administration 10903 New Hampshire Avenue

Silver Spring, MD 20993

www.fda.gov

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including

information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-

<u>devices/device-advice-comprehensive-regulatory-assistance</u>) and CDRH Learn (<u>https://www.fda.gov/training-and-continuing-education/cdrh-learn</u>). Additionally, you may contact the

Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See

the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-

<u>assistance/contact-us-division-industry-and-consumer-education-dice</u>) for more information or contact DICE

by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Elizabeth F. Claverie -S



CAPT Elizabeth Claverie, M.S.
Assistant Director
DHT4B: Division of Infection Control
and Plastic Surgery Devices
OHT4: Office of Surgical
and Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

April 15, 2009

TEST REPORT -

PN 83672A - Amended

CHEMICAL ANALYTICAL SERVICES

Prepared For:
Hartalega SDN. BDH
Ms. Nurul Aisyah Kong
No. 7 Kawasan Perusahaan Suria
Bestari Jaya
Selangor, 45600
Malaysia

Prepared By

Tiffany L Heller hemical Technician Approved By:

Ana C. Barbur, M.S.

Manager, Chemical & Pharmaceutical Services

An A2LA Accredited Testing Laboratory — Certificate Numbers 255.01 & 255.02 ISO 9001:2000 Registered

Member of ACIL: The American Council of Independent Laboratories

ACCREDITED
A Testing Lab

ISO 9001:2000

Registered



Letters and reports are for the exclusive use of the clients to whom they are addressed and shall not be reproduced, except in full, without the written permission of Akron Rubber Development Laboratory, Inc. (ARDL). The information contained herein applies to the specific material, products or processes tested or evaluated. No warranty of any kind is herein construed or implied. The liability of ARDL, Inc. shall be limited to the amount of consideration paid for services. ARDL, Inc. is accredited by AZLA for the test methods listed on the attached scope.

www.ardl.com

2887 Gilchrist Rd. | Akron, Ohio 44305 | answers@ardl.com Toll Free (800) 830-ARDL | Worldwide (330) 794-6600 | Fax (330) 794-6610



Testing. Development. Problem Solving.

April 15, 2009

Ms. Nurul Aisyah Kong Hartalega SDN. BHD

Page 1 of 3 - PN 83672A - Amended

SUBJECT:

Permeation testing per ASTM D 6978-05 on sample submitted by the above company. Wire

Transfer.

RECEIVED:

Glove sample identified as Nitrile Powder Free Examination Gloves (Blue) Code: ABLU.

TESTING CHEMOTHERAPY DRUGS:

Table 1. List of the Testing Chemotherapy Drugs, Sources, and Expiration Dates

TESTING CHEMOTHERAPY DRUGS	DRUG SOURCE
Carmustine (BCNU)	Sigma; Lot# 038K4008; Expiration 12/2009
Cisplatin	Sigma; Lot# 59H3657; Expiration 09/2009
Cyclophosphamide (Cytoxan)	Sigma; Lot# 068K1131; Expiration 1/2010
Dacarbazine (DTIC)	Hospira; Lot# U022223AA; Expiration 06/2010
Doxorubicin Hydrochloride	Teva; Lot#07N625; Expiration 10/2009
Etoposide (Toposar)	Teva; Lot# 31303976B; Expiration 9/2011
Fluorouracil	APP; Lot# 203867; Expiration 03/2010
Mitomycin C	Sigma, Lot# 048K1086; Expiration 01/2010
Methotrexate	Hospira; Lot# U024457AA; Expiration 05/2010
Paclitaxel (Taxol)	Dabur Oncology; Lot# PA08H00701; Exp. 05/2010
Thiotepa	Sigma; Lot#078K1526; Expiration 12/2009
Vincristine Sulfate	Hospira, Lot# U037139AA; Expiration 12/2009

COLLECTION MEDIA:

The collection media, which were selected, are listed in Table 2.

Table 2. Collection Media for Testing Chemotherapy Drugs

TEST DRUG AND CONCENTRATION	COLLECTION MEDIUM
Carmustine (BCNU), 3.3 mg/ml (3,300 ppm)	10% Ethanol Aqueous Solution
Cisplatin, 1.0 mg/ml (1,000 ppm)	Distilled Water
Cyclophosphamide (Cytoxan), 20 mg/ml (20,000 ppm)	Distilled Water
Dacarbazine (DTIC), 10.0 mg/ml (10,000 ppm)	Distilled Water
Doxorubicin Hydrochloride, 2.0 mg/ml (2,000 ppm)	Distilled Water
Etoposide (Toposar), 20.0 mg/ml (20,000 ppm)	Distilled Water
Fluorouracil, 50.0 mg/ml (50,000 ppm)	9.20 pH Sodium Hydroxide Solution
Methotrexate, 25 mg/ml (25,000 ppm)	Distilled Water
Mitomycin C, 0.5 mg/ml (500 ppm)	Distilled Water
Paclitaxel (Taxol), 6.0 mg/ml (6,000 ppm)	30% Methanol Aqueous Solution
Thiotepa, 10.0 mg/ml (10,000 ppm)	Distilled Water
Vincristine Sulfate, 1.0 mg/ml (1,000 ppm)	Distilled Water

www.ardl.com

2887 Gilchrist Rd. | Akron, Ohio 44305 | answers@ardl.com Toll Free (800) 830-ARDL | Worldwide (330) 794-6600 | Fax (330) 794-6610 Ms. Nurul Aisyah Kong Hartalega SDN. BHD

Page 2 of 3 - PN 83672A - Amended

TESTING CONDITIONS:

Standard Test Method Used:

Deviation From Standard Test Method:

Analytical Method:

Testing Temperature:

Collection System:

Specimen Area Exposed:

Selected Data Points:

Number of Specimens Tested:

Location Sampled From:

Comments/Other Conditions:

ASTM D 6978-05

Used 1" Permeation Cell

UV/VIS Spectrometry

35.0°C ± 2.0

Closed Loop

5.067 cm2

25/test

3/test

Cuff area

Magnetic stir bar was used in the sampling chamber

DETECTION METHOD OF CHEMICAL PERMEATION; UV/VIS ABSORPTION SPECTROMETRY:

Instrument: Perkin Elmer UV/VIS Spectrometer Lambda 25

UV/VIS Absorption Spectrometry was used to measure the absorbance of test chemicals, which permeated through the specimens into the collection medium. The collection medium was circulated in a closed loop at 11 ml/minute of flow rate through the testing period. Data collection was performed according to the programmed schedule by means of UV Winlab software from the Perkin Elmer Corporation. The list of the characteristic wavelengths is shown below.

Table 3. Characteristic Wavelengths used in UV/VIS Absorption Spectrometry

TESTING CHEMOTHERAPY DRUGS	WAVELENGTH (nm)
Carmustine (BCNU), 3.3 mg/ml (3,300 ppm)	229
Cisplatin, 1.0 mg/ml (1,000 ppm)	199
Cyclophosphamide (Cytoxan), 20 mg/ml (20,000 ppm)	200
Dacarbazine (DTIC), 10.0 mg/ml (10,000 ppm)	320
Doxorubicin Hydrochloride, 2.0 mg/ml (2,000 ppm)	232
Etoposide (Toposar), 20.0 mg/ml (20,000 ppm)	205
Fluorouracil, 50.0 mg/ml (50,000 ppm)	269
Methotrexate, 25 mg/ml (25,000 ppm)	303
Mitomycin C, 0.5 mg/ml (500 ppm)	217
Paclitaxel (Taxol), 6.0 mg/ml (6,000 ppm)	231
Thiotepa, 10.0 mg/ml (10,000 ppm)	199
Vincristine Sulfate, 1.0 mg/ml (1,000 ppm)	220

SAMPLE CHARACTERISTICS:

Table 4. Thickness characteristics for the tested specimens: Nitrile Powder Free Examination Gloves (Blue) Code: ABLU.

Testing Chemotherapy	Thickness (mm)			Weight/Unit Area	
Drugs	Sample 1	Sample 2	Sample 3	Average (mm)	(g/m2)
Carmustine (BCNU)	0.080	0.084	0.082	0.082	79.2
Cisplatin	0.086	0.082	0.088	0.085	79.2
Cyclophosphamide (Cytoxan)	0.087	0.083	0.081	0.084	79.2
Dacarbazine (DTIC)	0.086	0.080	0.084	0.083	79.2
Doxorubicin Hydrochloride	0.087	0.084	0.082	0.084	79.2
Etoposide (Toposar)	0.085	0.088	0.090	0.088	79.2
Fluorouracil	0.082	0.082	0.094	0.086	79.2
Methotrexate	0.081	0.084	0.087	0.084	79.2
Mitomycin C	0.082	0.082	0.084	0.083	79.2
Paclitaxel (Taxol)	0.086	0.081	0.082	0.083	79.2
Thiotepa	0.084	0.083	0.087	0.085	79.2
Vincristine Sulfate	0.088	0.084	0.082	0.085	79.2

Ms. Nurul Aisyah Kong Hartalega SDN. BHD

Page 3 of 3 - PN 83672A - Amended

RESULTS:

Table 5. Permeation Test Results on: Nitrile Powder Free Examination Gloves (Blue) Code: ABLU.

TEST CHEMOTHERAPY DRUG AND CONCENTRATION	MINIMUM BREAKTHROUGH DETECTION TIME (Specimen 1/2/3) (Minutes)	STEADY STATE PERM. RATE (Specimen 1/2/3) (µg/cm²/minute)	OTHER OBSERVATIONS
Carmustine (BCNU), 3.3 mg/ml (3,300 ppm)	35.80 (45.31,30.46,31.63)	1.24 (1.36,1.16,1.20)	Moderate swelling and no degradation
Cisplatin, 1.0 mg/ml (1,000 ppm)	No breakthrough up to 240 min.	N/A	Slight swelling and no degradation
Cyclophosphamide (Cytoxan), 20 mg/ml (20,000 ppm)	No breakthrough up to 240 min.	N/A	Slight swelling and no degradation
Dacarbazine (DTIC), 10.0 mg/ml (10,000 ppm)	No breakthrough up to 240 min.	N/A	Slight swelling and no degradation
Doxorubicin Hydrochloride, 2.0 mg/ml (2,000 ppm)	No breakthrough up to 240 min.	N/A	Slight swelling and no degradation
Etoposide (Toposar), 20.0 mg/ml (20,000 ppm)	No breakthrough up to 240 min.	N/A	Slight swelling and no degradation
Fluorouracil, 50.0 mg/ml (50,000 ppm)	No breakthrough up to 240 min.	N/A	Slight swelling and no degradation
Methotrexate, 25 mg/ml (25,000 ppm)	No breakthrough up to 240 min.	N/A	Slight swelling and no degradation
Mitomycin C, 0.5 mg/ml (500 ppm)	No breakthrough up to 240 min.	N/A	Moderate swelling and no degradation
Paclitaxel (Taxol), 6.0 mg/ml (6,000 ppm)	No breakthrough up to 240 min.	N/A	Moderate swelling and no degradation
Thiotepa, 10.0 mg/ml (10,000 ppm)	85.48 (105.33,75.52,75.60)	1.32 (1.33,1.32,1.32)	Slight swelling and no degradation
Vincristine Sulfate, 1.0 mg/ml (1,000 ppm)	No breakthrough up to 240 min.	N/A	Slight swelling and no degradation


Tiffany L. Heller

Chemical Technician, Chemical Services

AKRON RUBBER DEVELOPMENT LABORATORY, INC.

Ana C. Barbur, M.S,

Chemical and Pharmaceutical Services



Page Last Updated: 05/25/2020

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.

Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسى | English



Contains: 100 gloves x 10 boxes (by weight)

Nitrile Po Examinati


Fingertip Textured Powder Free Not Made with Natural Rubber Latex Chemo Drugs Tested

AQL 1.5

STICE

Made in Mala

Scanned with CamScanner







Contains: 100 gloves x 10 boxes (by weight)

Nitrile Powder Free Examination Gloves

Fingertip Textured
Powder Free
Not Made with
Natural Rubber Latex
Chemo Drugs Tested

Lab Chemical Tested Single-Use Only Ambidextrous Patient Examination Glove

AQL 1.5

ST CE NON STERILE

Made in Malaysia

A brand by

DIMUD



HARTALEGA: GloveOn PALOMA

Diamension of Carton box 26cm(L) x 26cm(W) x 26cm(H)

Weight in Carton box: Size S at 3.7kg Size M at 4.1kg Size L at 4.4kg

20GP FCL at 13,000 boxes

One carton 10 boxes One box 100 pieces